adakveo 10 mgml
novartis israel ltd - crizanlizumab - concentrate for solution for infusion - crizanlizumab 10 mg/ml - crizanlizumab - adakveo is indicated to reduce the frequency of vasoocclusive crises (vocs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
cosentyx 300mg2ml solution for injection in pre-filled syringe
novartis corporation (malaysia) sdn. bhd. - secukinumab -
fraizeron 300mg2ml solution for injection in pre-filled pen
novartis corporation (malaysia) sdn. bhd. - secukinumab -
scemblix 20 mg
novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 20 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation
scemblix 40 mg
novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 40 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation
potassium-novartis tablet (effervescent)
novartis pharmaceuticals canada inc - potassium chloride; potassium bicarbonate - tablet (effervescent) - 600mg; 400mg - potassium chloride 600mg; potassium bicarbonate 400mg - replacement preparations
novartis vaccines & diagnostics pty ltd - procleix ultrio plus assay
novartis vaccines & diagnostics pty ltd -
seebri breezhaler
novartis new zealand ltd - glycopyrronium bromide 0.063mg equivalent to glycopyrronium 0.05 mg; - powder filled inhalation capsule - 50 mcg - active: glycopyrronium bromide 0.063mg equivalent to glycopyrronium 0.05 mg excipient: lactose monohydrate magnesium stearate orange capsule (novartis) - once-daily maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (copd).
tasigna 200 mg
novartis israel ltd - nilotinib as monohydrate - capsules - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
tasigna 150 mg
novartis israel ltd - nilotinib as hydrochloride monohydrate - capsules - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.